Find more content written by:  Pierre Jamet; Baohong Ji
  • Volume 62 , Number 4
  • Page: 622
CORRESPONDENCE

Relapse after long-term follow up of multibacillary patients treated by WHO multidrug regimen

Pierre Jamet; Baohong Ji






To the Editor:

Up to 1993, more than 4 million leprosy patients (5) in the world have completed their treatment with multidrug therapy (MDT) recommended by a WHO Study Group (4) in 1982. Data from routine leprosy control programs have indicated that, after completion of M DT, the relapse rates are well below 1% (1,6). However, the low relapse rates must be interpreted with great caution, because the durations of follow up in the majority of patients arc relatively short and the relapses after treatment with any rifampin-containing regimens occur late, at least 5 ± 2 years after starting treatment.

Thirty-five multibacillary patients, treated with MDT for 2 years between 1984 and 1986 at the Institute Marchoux, with all drugs administered under supervision, have been seen at least once later than 12 months after completing MDT. Relapse was diagnosed if two or the following three criteria were met: a) increase of bacterial index (HI) by at least 2+ over the previous value, b) occurrence of a definite new leprosy skin lesion, and c) demonstration of viable organisms by mouse foot pad inoculation (2,3).

After 41.9 ± 12.1 months of follow up, only one patient relapsed for a relapse rate of 2.9% or 0.8 per 100 patient-years (3). Additional follow up was done. Six additional relapses were diagnosed during the next 2 ½ years for an overall relapse rate of 20.0% or 3.3 per 100 patient-years. The mean interval between stopping treatment and the appearance of relapse was 62.7 ± 18.7 months, a figure similar to that of relapses after stopping treatment with other rifampin-containing regimens.

To date, the relapsed cases had significantly greater bacterial loads before or at the end of the 2 years of MDT: 38.9% and 41.7% relapsed, respectively, among patients who had an average BI > 4.0 before MDT or BI > 3.0 at the end of MDT; whereas the relapse rates were respectively 0% and 8.7% among patients who had an average BI <4.0 before MDT or BI <3.0 at the end of MDT. In other words, relapse was significantly more frequent among patients with BI >4.0 before MDT or BI >3.0 at the end of MDT.

A full manuscript, analyzing the long-term, followup results has been submitted to this Journal.

 

- Pierre Jamet, M.D.

Institui Marchoux
Bamako, Mali

- Baohongji, M.D.

Faculte de Medecine Pitie-Salpetriere
Paris, France

 

REFERENCES

1. ALM Consensus Development Conference on the Chemotherapy of Leprosy. Consensus development statement on the chemotherapy of leprosy. Int. J. Lepr. 60(1992)644-652.

2. Jamet, P., Blanc, L., Faye, O. C, Traore, I. and Bobin, P. Relapses after a single dose rifampin in skin smear negative multibacillary patients after dapsone monotherapy. Int. J. Lepr. 62(1994)209-214.

3. Marchoux Chemotherapy Study Group. Relapses in multibacillary leprosy patients after stopping treatment with rifampin-containing regimens. Int. J. Lepr. 60(1992)525-535.

4. WHO Study Group. Chemotherapy of leprosy for control programmes. Geneva: World Health Organization, 1982. Tech. Rep. Scr. 675.

5. World Health Organization. Progress towards the elimination of leprosy as a public health problem. Weekly Epidemiol. Rec. 68(1993)181-188.

6. World Health Organization Leprosy Unit. Risk of relapse in leprosy. WHO document WHO/CTD/ LEP/94.1.

2019 © International Journal of Leprosy and other Mycobacterial Diseases all right reaserved GN1